Future oncology
-
EMA licensed eribulin mesylate in 2011 for women with advanced breast cancer already treated with at least two lines of chemotherapy, including anthracyclines and taxanes. Azienda Sanitaria Firenze experience is reported to assess the efficacy and safety of eribulin in the real-life setting. ⋯ Eribulin maintains its activity out of clinical trials, without unexpected toxicities.
-
The objective of this study was to analyze the impact of visceral metastases in castration-resistant prostate cancer (CRPC) treated with abiraterone. ⋯ Visceral disease appears to be an important predictor of clinical outcome in CRPC patients treated with abiraterone.
-
Oncologic therapeutics has evolved enormously as we entered the 21st century. Unfortunately, the treatment of advanced urothelial cancer has remained unchanged over the last two decades despite a better understanding of the genetic alterations in bladder cancer. Pathways such as the PI3K/AKT3/mTOR and FGFR have been implicated in urothelial bladder cancer. ⋯ Recently, researchers have been successful in manipulating the systemic immune response to mount antitumor effects in melanoma, lung cancer and lymphoma. Historically, intravesical Bacillus Calmette-Guérin immunotherapy has been highly active in nonmuscle invasive bladder cancer. Early data suggest that immune checkpoint inhibitors will soon prove to be another cornerstone in the treatment armamentarium of advanced bladder cancer.
-
NS are commonly used by patients affected by cancer. Patients are using these supplements mainly to improve their quality of life in their cancer trajectory. An open and empathic approach to this use is essential for successful patient–doctor communication. An informed approach that takes into consideration NS that are safe, with clues of possible effectiveness can lead to a better decision-making and trust in this communication process.